Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: - Below 500,000 yuan: 27 individuals (39%) - 500,000-1,000,000 yuan: 29 individuals (42%) - 1,000,000-2,000,000 yuan: 10 individuals (15%) - 2,000,000-3,000,000 yuan: 2 individuals (3%) - Above 3,000,000 yuan: 1 individual (1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - The educational background indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earning Company Secretaries - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu: 2.5587 million yuan - Cao Wei from Jichuan Pharmaceutical: 2.4107 million yuan - Yu Jie from Tianjin Tasly: 2.525 million yuan - Wu Rui from Yiling Pharmaceutical: 1.89 million yuan - Jiang Xianhong from Yibai Pharmaceutical: 1.3935 million yuan - Their tenure at the companies ranges from less than 1 year to 15 years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies: - Less than 10 meetings: 41 companies (59%) - 10-100 meetings: 17 companies (25%) - 100-300 meetings: 9 companies (13%) - 300-1000 meetings: 2 companies (3%) [7] - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical: 410 meetings - Qizheng Pharmaceutical: 404 meetings - Yunnan Baiyao: 298 meetings - Jinghua Pharmaceutical: 221 meetings - Pianzihuang: 207 meetings [9]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - The data indicates that over 21% of company secretaries earn more than 1 million yuan annually [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries shows that 39% earn below 500,000 yuan, 42% earn between 500,000 and 1 million yuan, 15% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] Age and Educational Background - The age distribution of company secretaries shows that 42% are between 40-50 years old, 29% are over 50, and 26% are under 40 [1] - In terms of educational qualifications, 5% have an associate degree, 42% hold a bachelor's degree, 49% have a master's degree, and 4% possess a doctoral degree, with over half holding a master's degree or higher [3] Top Earning Company Secretaries - The top five highest-paid company secretaries are from Huaren Sanjiu, Jichuan Pharmaceutical, Tianshili, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries of 2.5587 million yuan, 2.4107 million yuan, 2.525 million yuan, 1.89 million yuan, and 1.3935 million yuan respectively [7] - The tenure of these top earners varies, with some having less than one year of service and others having up to 15 years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 59% of companies hosting fewer than 10 meetings annually [7] - The top five companies with the most investor meetings are Zoli Pharmaceutical, Qizheng Tibetan Medicine, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with 410, 404, 298, 221, and 207 meetings respectively [9]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - The data indicates that over 21% of company secretaries earn more than 1 million yuan annually [1] Group 1: Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [7] - The distribution of salaries shows that 39% earn below 500,000 yuan, 42% earn between 500,000 and 1 million yuan, 15% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [7] - The top five highest-paid company secretaries are from Huaren Sanjiu, Jichuan Pharmaceutical, Tianshili, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries of 2.5587 million yuan, 2.4107 million yuan, 2.525 million yuan, 1.89 million yuan, and 1.3935 million yuan respectively [7] Group 2: Age Distribution - Company secretaries aged between 40 and 50 constitute 42% of the market, while those over 50 account for 29%, and those under 40 make up 26% [3] - The youngest company secretary is 32 years old, representing Te Yi Pharmaceutical [3] Group 3: Educational Background - The educational background of company secretaries shows that 5% have an associate degree, 42% hold a bachelor's degree, 49% have a master's degree, and 4% possess a doctoral degree [5] - More than half of the company secretaries hold a master's degree or higher, with only three having a doctoral degree [5] Group 4: Investor Engagement - There is significant variation in the number of investor meetings held by listed companies, with 59% of companies hosting fewer than 10 meetings annually [9] - The top five companies with the most investor meetings are Zoli Pharmaceutical, Qizheng Tibetan Medicine, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with 410, 404, 298, 221, and 207 meetings respectively [9]

Group 1 - The company held its 20th meeting of the 10th Board of Directors on July 10, 2025, via remote voting, with all 7 participating directors voting [1][2] - The board approved the appointment of Mr. Zhang Chaoyang as the Secretary of the Board, effective immediately until the end of the current board's term [1][2] - The board also approved the adjustment of the Audit Committee, electing Mr. Xing Yajiang as a member, while the other members remain unchanged [2]

证券代码：600080 证券简称：金花股份 公告编号：临 2025-031 金花企业（集团）股份有限公司 关于调整董事会审计委员会委员及聘任董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会审计委员会委员辞职及调整董事会审计委员会委员的情况 金花企业（集团）股份有限公司（以下简称"公司"）董事会于近日收到 公司董事张朝阳先生递交的书面辞职报告，张朝阳先生因个人工作调整原因辞 去第十届董事会审计委员会委员职务，辞职后，张朝阳先生将继续担任公司董 事。该辞职报告自送达公司董事会之日起生效。 根据《公司法》、《上海证券交易所股票上市规则》、《上市公司章程指 引》等相关规定，为进一步完善公司治理结构，保障公司规范运作，董事会选 举邢雅江先生为公司第十届董事会审计委员会委员，任期自公司董事会审议通 过之日起至第十届董事会任期届满之日止。除上述调整外，公司第十届董事会 审计委员会委员保持不变。 调整前后公司第十届董事会审计委员会委员情况如下： 调整前：吴雅婕、刘晓娟、张朝阳 上述事项已经公司 2025 年 ...

金花企业（集团）股份有限公司 证券代码：600080 股票简称：金花股份 编号：临 2025-032 （二）通过《关于调整董事会审计委员会委员的议案》 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票 第十届董事会第二十次会议决议公告 根据《公司法》、《上海证券交易所股票上市规则》、《上市公司章程指引》等 相关规定，张朝阳先生辞去担任的公司审计委员会委员职务。为进一步完善公司 治理结构，保障公司规范运作，董事会选举邢雅江先生为公司第十届董事会审计 委员会委员，任期自公司董事会审议通过之日起至第十届董事会任期届满之日 止。除上述调整外，公司第十届董事会审计委员会委员保持不变。调整后，公司 第十届董事会审计委员会成员为：吴雅婕、刘晓娟、邢雅江。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 金花企业（集团）股份有限公司（以下简称"公司"）第十届董事会第二十 次会议通知于 2025 年 7 月 9 日以电子邮件及微信方式发出，会议于 2025 年 7 月 10 日以通讯表决方式召开。应参与表决 ...

Core Viewpoint - The company has received a case acceptance receipt from the public security authority regarding a lawsuit against its former actual controller and controlling shareholder for misappropriating company funds [2][3]. Group 1: Legal Proceedings - The company is currently in the litigation stage after receiving the case acceptance receipt from the public security authority [2]. - The company has been involved in multiple lawsuits initiated by small investors, totaling 590 cases with a cumulative compensation amount of 43.982 million yuan [3]. - The company is actively pursuing legal actions against its former controlling shareholder, Jin Hua Investment Holding Group Co., Ltd., and its former actual controller, Wu Yijian, to protect the rights of the company and its shareholders [3][4]. Group 2: Financial Impact - The misappropriation of funds amounts to 16.772 million yuan, which was allegedly facilitated through contracts with third parties and related parties [3]. - The company has reported that its business operations remain normal despite the ongoing legal issues, although the impact of the case on the company is uncertain [4]. Group 3: Information Disclosure - The company commits to timely information disclosure regarding the progress of the case and will cooperate with the economic crime investigation team [4]. - The designated media for information disclosure includes the Shanghai Securities Journal and the Shanghai Stock Exchange website [4].

重要内容提示： 金花企业（集团）股份有限公司（以下简称"公司"或"金花股份"）于 2021 年 3 月 23 日、2021 年 9 月 16 日、2021 年 9 月 25 日、2021 年 9 月 28 日、 2021 年 11 月 13 日、2022 年 5 月 13 日、2023 年 2 月 11 日、2023 年 6 月 17 日、 2024 年 1 月 27 日、2025 年 1 月 18 日分别披露了《金花企业（集团）股份有限 公司关于涉及中小投资者诉讼的公告》及进展公告（具体内容详见公告"临 2021-022、临 2021-055、临 2021-057、临 2021-058、临 2021-062、临 2022- 046、临 2023-008、临 2023-034、临 2024-003、临 2025-004"号）。"临 2025-004 号"公告明确：对于该事项引发的投资者诉讼对公司造成的损失，公 司将积极采取包括诉讼在内的各项法律措施，追究原控股股东金花投资控股集 团有限公司及原实际控制人吴一坚法律责任，依法维护公司和广大股东的合法 权益，并将持续关注案件的进展情况，及时履行信息披露义务。 因原 ...

Core Viewpoint - The inquiry letter from the Shanghai Stock Exchange regarding the information disclosure of Jinhua Enterprise (Group) Co., Ltd. highlights issues related to the use of raised funds and project management, particularly concerning the new factory relocation and expansion project [1][2]. Group 1: Fundraising and Project Management - The company raised 628 million yuan through a private placement, with 480 million yuan allocated for the new factory relocation and expansion project. As of the end of 2024, 369 million yuan had been invested in this project [1]. - A contract was signed with Shaanxi Hongyuan Zhenye Industrial Co., Ltd. for the renovation and minor works of the public areas of the pharmaceutical plant, with an initial payment of 18 million yuan made [1][2]. - The inquiry raised concerns about the management of raised funds and project budgets, specifically regarding the prepayment of large engineering amounts and whether there was any disguised fund occupation [1][2]. Group 2: Contractual Details and Payment Terms - The contract with Shaanxi Hongyuan includes specific construction content, a bill of quantities, acceptance standards, and payment schedule [2][3]. - The payment schedule stipulates that 80% of the payment is made based on the completed work verified by the project owner, with payments made by the 10th of each month for the previous month's work [4]. - The company has made significant prepayments exceeding 5 million yuan for various projects, including a prepayment of 42 million yuan for a total project cost of 280 million yuan, and 10 million yuan for another project [4][5]. Group 3: Supplier Relationships and Compliance - The company provided details on the latest fund usage for the investment projects, totaling 393.13 million yuan, which includes engineering costs, equipment costs, and other related expenses [2][4]. - Among the top suppliers in the past two years, some did not follow the bidding procedures, particularly Shaanxi Hongyuan and Shaanxi Fuhuihui Decoration Engineering Co., Ltd. [7][8]. - The company confirmed that the main suppliers do not have any direct or indirect relationships with the actual controllers or other shareholders, except for Shaanxi Juchi Construction Engineering Monitoring Co., Ltd., which is an associated party [9][10].

国金证券股份有限公司关于 金花企业(集团)股份有限公司 2024 年年度报告的信息披露监管问询函之核查意见 上海证券交易所： 贵所 2025 年 5 月 27 日下发《关于金花企业（集团）股份有限公司 2024 年 年度报告的信息披露监管问询函》（上证公函【2025】0660 号）（以下简称"问 询函"），国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）现 就《问询函》中的相关问题进行了落实，具体回复如下： 一、《问询函》问题 关于募集资金投资项目。年度报告及募集资金使用专项说明显示，前期公司 通过非公开发行股票募集资金 6.28 亿元，其中 4.8 亿元用于"新厂区搬迁扩建 项目"，截至 2024 年年末，"新工厂搬迁扩建项目"累计投入 3.69 亿元，公 司于 2024 年 11 月 25 日签订协议，由陕西弘源振业实业有限公司（以下简称 陕西弘源）承接公司制药厂搬迁扩建项目公共区域装修及零星工程、外立面改造 提升等，合同签订后一次性支付工程款 1800 万元。截至 2025 年 4 月 23 日， 该工程款扣除实际工程完成量金额后，余款已全部收回，募集资金使用及工程预 算管理存在问题。请公司： ...